Oculomotor signatures differentiate Alzheimer’s disease from healthy controls and are associated with clinical severity

Background Oculomotor dysfunction is increasingly recognized in Alzheimer’s disease (AD), but conventional eye-tracking approaches have limited clinical scalability. Methods We investigated whether oculomotor features acquired using a tablet-based eye-tracking platform could provide an objective signature of AD and clinical disease severity. Seventy-five participants with AD and 75 cognitively and neurologically healthy controls (HC) completed five oculomotor tasks using an iPad-based eye-tracking platform. A broad set of oculomotor features was used to develop 13 higher-order composite features summarizing recurrent task- and signal-level patterns. AD–HC classification was evaluated across complementary model families using repeated nested cross-validation, and associations between classifier output, composite measures, cognition, and clinical severity were subsequently examined. Results The best model achieved an AUC of 0.906, balanced accuracy of 0.860, sensitivity of 85.3%, and specificity of 86.7%, with broadly similar performance across regularized linear and nonlinear models. Discrimination performance increased with disease severity, with sensitivity rising from 73.0% in participants with CDR 0.5 to 96.8% with CDR 1.0, and misclassified participants tended to show oculomotor profiles resembling the opposite diagnostic group. Within AD, higher classifier-derived probability was associated with poorer MoCA and MMSE performance and greater CDR-SB severity. Conclusion These findings support the presence of a compact, multidomain oculomotor signature of AD that reflects both diagnostic status and clinical disease severity. Although independent validation of the predefined composites and classifier is needed to establish their generalizability, the results highlight the potential of tablet-based eye tracking as a scalable and objective approach for capturing these signals.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2026-11-18
DOI
https://doi.org/10.1186/s13195-026-02262-7
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oculomotor signatures differentiate Alzheimer’s disease from healthy controls and are associated with clinical severity

Patrice Voss, Lydia Ouellet, Nils A. Koch, Etienne de Villers‐Sidani et al.
2 links
Alzheimer s Research & Therapy
Dementia and Cognitive Impairment Research
article

Oculomotor signatures differentiate Alzheimer’s disease from healthy controls and are associated with clinical severity

Patrice Voss, Lydia Ouellet, Nils A. Koch, Etienne de Villers‐Sidani, Paul Steven Giacomini, Maryse E. Thomas, Simon Ducharme
article en

Abstract

Background Oculomotor dysfunction is increasingly recognized in Alzheimer’s disease (AD), but conventional eye-tracking approaches have limited clinical scalability. Methods We investigated whether oculomotor features acquired using a tablet-based eye-tracking platform could provide an objective signature of AD and clinical disease severity. Seventy-five participants with AD and 75 cognitively and neurologically healthy controls (HC) completed five oculomotor tasks using an iPad-based eye-tracking platform. A broad set of oculomotor features was used to develop 13 higher-order composite features summarizing recurrent task- and signal-level patterns. AD–HC classification was evaluated across complementary model families using repeated nested cross-validation, and associations between classifier output, composite measures, cognition, and clinical severity were subsequently examined. Results The best model achieved an AUC of 0.906, balanced accuracy of 0.860, sensitivity of 85.3%, and specificity of 86.7%, with broadly similar performance across regularized linear and nonlinear models. Discrimination performance increased with disease severity, with sensitivity rising from 73.0% in participants with CDR 0.5 to 96.8% with CDR 1.0, and misclassified participants tended to show oculomotor profiles resembling the opposite diagnostic group. Within AD, higher classifier-derived probability was associated with poorer MoCA and MMSE performance and greater CDR-SB severity. Conclusion These findings support the presence of a compact, multidomain oculomotor signature of AD that reflects both diagnostic status and clinical disease severity. Although independent validation of the predefined composites and classifier is needed to establish their generalizability, the results highlight the potential of tablet-based eye tracking as a scalable and objective approach for capturing these signals.

Alzheimer s Research & Therapy
Montreal Neurological Institute and Hospital (CA), Douglas Mental Health University Institute (CA), McGill University (CA)
Ministère de l'Économie, de l’Innovation et des Exportations du Québec, Québec Consortium for Drug Discovery, Weston Family Foundation
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon